BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a sell rating to a hold rating in a report released on Saturday morning.

Other research analysts have also recently issued reports about the stock. Robert W. Baird reiterated a buy rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 19th. Wedbush upgraded shares of Ultragenyx Pharmaceutical from a neutral rating to an outperform rating and set a $62.00 price objective for the company in a report on Thursday, September 14th. Canaccord Genuity set a $80.00 price objective on shares of Ultragenyx Pharmaceutical and gave the company a buy rating in a report on Tuesday, December 5th. Barclays lifted their price objective on shares of Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the company an equal weight rating in a report on Tuesday, December 5th. Finally, Raymond James Financial reiterated a buy rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, December 5th. Ten investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $72.40.

Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at $48.24 on Friday. The stock has a market cap of $2,163.95, a PE ratio of -6.92 and a beta of 1.83. Ultragenyx Pharmaceutical has a twelve month low of $43.14 and a twelve month high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.87). The business had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.02 million. The firm’s quarterly revenue was up 81.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.64) earnings per share. equities research analysts expect that Ultragenyx Pharmaceutical will post -7.3 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. boosted its holdings in Ultragenyx Pharmaceutical by 7.7% during the second quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 248 shares during the last quarter. Amalgamated Bank boosted its holdings in Ultragenyx Pharmaceutical by 7.6% during the second quarter. Amalgamated Bank now owns 4,980 shares of the biopharmaceutical company’s stock worth $309,000 after purchasing an additional 352 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in Ultragenyx Pharmaceutical by 12.0% during the second quarter. Pacer Advisors Inc. now owns 3,402 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 365 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Ultragenyx Pharmaceutical by 1.0% during the second quarter. Principal Financial Group Inc. now owns 73,412 shares of the biopharmaceutical company’s stock worth $4,559,000 after purchasing an additional 722 shares during the last quarter. Finally, California Public Employees Retirement System boosted its holdings in Ultragenyx Pharmaceutical by 2.1% during the second quarter. California Public Employees Retirement System now owns 39,100 shares of the biopharmaceutical company’s stock worth $2,429,000 after purchasing an additional 800 shares during the last quarter. Institutional investors and hedge funds own 94.10% of the company’s stock.

WARNING: “Ultragenyx Pharmaceutical (RARE) Upgraded at BidaskClub” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/ultragenyx-pharmaceutical-rare-upgraded-at-bidaskclub/1799521.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with Analyst Ratings Network's FREE daily email newsletter.